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 SUMMARY 
In both humans and dogs, obesity is a serious disorder with increasing prevalence. Overweight 
individuals are predisposed to several co-morbidities, such as orthopedic disorders, and shorter 
life expectancy.  
 
In humans, obesity is also associated with reduced fertility. Obese men have lowered serum 
concentration of the sex hormones testosterone and Anti-Müllerian Hormone (AMH). These 
sex hormones play an important role in fertility since testosterone supports spermatogenesis 
and promotes libido, while AMH is a marker of Sertoli cell maturation.  
 
An association between body condition score (BCS) and serum concentrations of testosterone 
and AMH has not previously been investigated in male dogs. The aim of this study was to 
investigate the relationship between BCS and serum concentration of testosterone and AMH in 
clinically healthy, intact male Labrador retrievers.  
 
Twenty-eight show-type Labrador retrievers participated in the study. The dogs were grouped 
as lean or overweight according to the BCS, a nine-point scale. Twelve dogs were classified as 
lean (BCS 4-5) and 16 were classified as overweight (BCS 6-8). Blood samples were collected 
and testosterone and AMH were measured by enzyme-linked immunosorbent assays (ELISAs). 
Median concentration and inter-quartile range was 9.6 ng/mL (7.4-14.1) for AMH and 9.7 
nmol/L (6.3-15.4) for testosterone. The AMH concentration ranged between 5.2 and 22 ng/mL. 
The testosterone concentration ranged between 1.6 and 20.2 nmol/L. 
 
The hypothesis of this study was that overweight dogs have lower testosterone and AMH serum 
concentrations than lean dogs, but the results showed that serum concentrations of testosterone 
and AMH did not differ significantly between lean and overweight dogs. This could be due to 
that the BCS was too low in the overweight dogs (only mild overweight), or that the sample 
population was too small and the power of the study thus limited.  
 
To conclude, in this study BCS had no impact on serum concentration of testosterone or AMH 
in male dogs.  
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
SAMMANFATTNING 
Övervikt är en allvarlig sjukdom med ökande prevalens hos både människor och hundar. 
Överviktiga individer lider ofta av flertalet sekundära hälsoeffekter, exempelvis ortopediska 
sjukdomar. Överviktiga individer riskerar också kortare livslängd än normalviktiga individer.  
 
Hos människa är övervikt också associerat med nedsatt fertilitet. Överviktiga män har lägre 
serumkoncentration av könshormonerna testosteron och anti-mülleriskt hormon (AMH). Dessa 
könshormoner spelar en viktig roll för fertiliteten, då testosteron stödjer spermatogenesen och 
ökar könsdriften, medan AMH är en markör för sertolicellsmognad.  
 
Sambandet mellan hull och serumkoncentration av testosteron och AMH har inte tidigare 
undersökts hos hanhundar. Målet med den här studien var att undersöka sambandet mellan hull 
och serumkoncentration av testosteron och AMH hos kliniskt friska, intakta hanhundar av rasen 
labrador retriever. 
 
I studien deltog 28 labrador retrievers av utställningstyp. Hundarna klassificerades som 
normalviktiga respektive överviktiga enligt den niogradiga BCS-skalan. Tolv hundar 
klassificerades som normalviktiga (BCS 4-5) och 16 klassificerades som överviktiga (BCS 6-
8). Blodprov samlades in varpå testosteron och AMH analyserades genom enzymkopplade 
immunadsorberande analyser (ELISA). Mediankoncentrationen och kvartilavståndet var 9,6 
ng/mL (7,4-14,1) för AMH och 9,7 nmol/L (6,3-15,4) för testosteron. AMH-koncentrationen 
varierade mellan 5,2 och 22 ng/mL. Testosteronkoncentrationen varierade mellan 1,6 och 20,2 
nmol/L.  
 
Hypotesen för denna studie var att överviktiga hundar har lägre serumkoncentration av 
testosteron och AMH än normalviktiga hundar, men resultaten visade att serumkoncentrationen 
av testosteron och AMH inte skilde sig signifikant mellan normalviktiga och överviktiga 
hundar. Resultaten kan bero på att de överviktiga hundarna bara var lindrigt överviktiga (vilket 
gör skillnaden mellan normalviktiga och överviktiga hundar liten), eller att studiepopulationen 
var för liten och att studiens styrka (power) därför blev begränsad. 
 
Sammanfattningsvis hade hull i denna studie inte någon inverkan på serumkoncentrationerna 
av testosteron och AMH hos hanhundar.  
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INTRODUCTION 
Obesity is the most common nutritional disorder in cats and dogs (Hoenig, 2010). The 
prevalence of obesity in dogs has increased over the last decades, from 20-30 % in the 70’s to 
around 40 % at the beginning of the twenty-first century (Mason, 1970, Edney and Smith, 1986, 
McGreevy et al., 2005, Colliard et al., 2006, Lund et al., 2006). 
 
A major concern regarding the obese state in dogs is the association with secondary health 
conditions such as orthopedic disorders (e.g. osteoarthritis and ruptured cruciate ligament) 
(Impellizeri et al., 2000, Lund et al., 2006). Obese dogs also suffer from shorter life expectancy 
(Kealy et al., 2002). 
 
In humans, obesity is associated with several co-morbidities (Hubert et al., 1983, Must et al., 
1999) and reduced fertility (The Rotterdam group, 2004, Cabler et al., 2010). In men, obesity 
is associated with lowered serum concentration of the sex hormones testosterone and Anti-
Müllerian Hormone (AMH) (Fejes et al., 2006, Håkonsen et al., 2011, Pietiläinen et al., 2011, 
Pellitero et al., 2012, Robeva et al., 2012). The sex hormones play an important role in fertility 
since testosterone supports spermatogenesis and AMH reflects Sertoli cell maturation (Rey et 
al., 1993, Rajpert-De Meyts et al., 1999, Feldman and Nelson, 2004). An association between 
body condition score (BCS) and serum concentrations of testosterone and AMH has not been 
investigated in male dogs. The objective of this study was to investigate the relationship 
between BCS and serum concentration of testosterone and AMH in clinically healthy male 
Labrador retrievers, a dog breed prone to obesity (Colliard et al., 2006, Lund et al., 2006, Raffan 
et al., 2014). 
 
The hypothesis was that overweight dogs have lower testosterone and AMH concentrations 
than lean dogs. If this statement holds true, it will give us yet another reason to control body 
weight and avoid obesity in companion dogs. It could also influence dog breeding towards a 
slimmer, and thus healthier, body ideal.  
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LITERATURE REVIEW 
Obesity 
The definition of obesity is ”accumulation of excess body fat” (Toll et al., 2010). Obesity occurs 
when energy expenditure is less than energy intake, which leads to excess storage of 
triglycerides in adipose tissue (Hoenig, 2010). Animals in ideal body condition have 15 to 20% 
body fat.  
 
In both humans and dogs, the term “obesity” and “overweight” is distinguished from one 
another. In humans, the Body Mass Index (BMI) is commonly used to classify overweight and 
obesity. BMI is defined as a person’s weight in kilograms divided by the square of his height 
in meters (kg/m2). According to the World Health Organization (WHO), a BMI greater than or 
equal to 25 is overweight, while a BMI greater than or equal to 30 is obesity (WHO, 2015). 
 
Instead in dogs, Relative Body Weight (RBW) may be used in defining overweight and obesity. 
RBW is defined as the animal’s current weight divided by its estimated optimal weight. RBW 
for overweight dogs is between 10-20% above optimal weight. RBW for obese dogs is >20% 
above optimal weight (Toll et al., 2010). In another study, an excess of approximately 20 to 25 
% above ideal bodyweight is regarded as obesity (Laflamme, 1997). 
 
Obesity in humans 
In humans, obesity is a global health problem with increasing prevalence. In 2003-2004, a study 
conducted on 4431 adults in the US reported the prevalence of obesity to 31.1 % among men 
and 33.2 % among women (Ogden et al., 2006). An international meta-analysis published in 
2014 showed similar results; the proportion of male overweight had increased from 28.8 % in 
1980 to 36.9 % in 2013. The same pattern was seen in women, where overweight had increased 
from 29.9 % in 1980 to 38.0 % in 2013 (Ng et al., 2014). According to WHO, more than 1.9 
billion adults were overweight in 2014, of whom 600 million were obese (WHO, 2015).  
 
A serious concern regarding obesity in humans is its association with several co-morbidities. 
Two big studies conducted on 5 209 and 16 884 individuals respectively, showed that obesity 
is a risk factor for cardiovascular disease, type 2 diabetes mellitus, high blood pressure, 
gallbladder disease and osteoarthritis (Hubert et al., 1983, Must et al., 1999). In another smaller 
study, obesity was also associated with pancreatitis, chronic fatigue and insomnia (Patterson et 
al., 2004).  
 
Moreover, obesity is associated with subfertility in both men and women. In general, obesity 
affects male fertility in three different ways; by altered semen parameters (e.g. decreased sperm 
concentration, abnormal sperm morphology and abnormal sperm motility), altered profile of 
sex hormones, and by physical disorders such as erectile dysfunction (Cabler et al., 2010). In 
women, obesity is associated with e.g. polycystic ovary syndrome (PCOS), a syndrome causing 
chronic anovulation (The Rotterdam group, 2004). 
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Obesity in dogs 
In both cats and dogs, obesity is the most common nutritional disorder, and is in fact regarded 
as a pandemic (Hoenig, 2010). The prevalence of obesity is increasing in dogs. It was 20-30 % 
in the 70’s and increased to around 40 % at the beginning of the twenty-first century (Mason, 
1970, Edney and Smith, 1986, McGreevy et al., 2005, Colliard et al., 2006, Lund et al., 2006). 
 
Like in humans, the obese state in dogs is associated with several secondary health conditions 
such as orthopedic disorders. In an epidemiological study conducted on 21 754 dogs during one 
year in the U.S., obese adult dogs were more likely to be diagnosed with ruptured cruciate 
ligament (odds ratio 2.1). Moreover, the prevalence of osteoarthritis was 4.2 % in obese and 
4.0 % in overweight individuals, compared to 2.4 % in normal weight individuals (Lund et al., 
2006). In another study, nine dogs with hind limb lameness due to osteoarthritis were fed a 
restricted-calorie diet for 10 to 19 weeks. At the end of the study, both body weight and hind 
limb lameness were significantly decreased (Impellizeri et al., 2000). Kealy et al. (2002) also 
report that obese dogs suffer from shorter life expectancy, in a study where restrictively fed 
Labradors had significantly longer median life span compared to dogs fed ad libitum. 
 
In dogs, breed is a risk factor for obesity. Retrievers, and particularly Labrador retrievers have 
an increased risk according to several studies (Edney and Smith, 1986, Colliard et al., 2006, 
Lund et al., 2006, Corbee, 2013). Interestingly, results from a recent study suggests that 
Labrador retrievers may have a mutation in the POMC gene, responsible for normal energy 
homeostasis, making them more prone to obesity (Raffan et al., 2014). In Sweden, the Swedish 
kennel club reported that the Labrador retriever breed as a whole decreased significantly in 
weight between 2005 and 2013. However, the Labrador retriever breed in Sweden is divided 
into two types; the show type and the working gun dog type (The Swedish Labrador Club, 
2014), hence the results probably depend on the fact that the much lighter working gun dog 
type is increasing in its popularity in Sweden (Andersson Linda, DVM, Swedish Kennel Club, 
personal communication, 2015). 
 
Today, several methods are available for classification of overweight and obesity in dogs. 
(Mawby et al., 2004), of which one is the Body Condition Score (BCS). BCS is a semi-
quantitative assessment of body composition. By visual observation and palpation of the ribs, 
the dog scores into a nine-point scale (Table 1). In 1997, Laflamme et al. validated BCS against 
dual energy X-ray absorptiometry (DEXA), which is the gold standard method for 
determination of body fat and lean body mass in dogs. Body Condition Scoring (BCS) is since 
then commonly used among practitioners as a tool for obesity assessment in dogs (Laflamme, 
1997, Mawby et al., 2004). 
 
 
 
 
 
 
Table 1. The Body Condition Score system in dogs (adapted after Laflamme, 1997).  
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The male reproductive system 
The main function of the male reproductive tract is to produce and store male gametes 
(spermatozoa), and to produce and secrete male sex hormones (androgens). The androgen 
produced in the greatest quantity is testosterone.  
 
Hormonal regulation 
The hormones involved in the regulation of the male reproductive system are part of the 
hypothalamic-pituitary-gonadal axis. From hypothalamus, a gonadotropin releasing hormone 
(GnRH) is transported to the anterior pituitary, from where the two gonadotropic hormones 
follicle stimulating hormone (FSH) and luteinizing hormone (LH) are released. FSH and LH 
then exert their effect on the male gonads. 
 
The hypothalamic-pituitary-gonadal axis is regulated through a negative feedback control 
system, where GnRH secretion is inhibited by both testosterone from the gonads, and by 
FSH/LH from the anterior pituitary (Figure 1). 
 
Body Condition Score  Designation 
1  Emaciated 
2                         Very thin 
3  Thin 
4  Underweight 
5  Ideal 
6  Overweight* 
7  Heavy 
8  Obese 
9 
 
 Grossly obese 
* Dogs with BCS 6 or above had palpable fat deposits.  
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Figure 1. The hypothalamic-pituitary-gonadal axis and its negative feedback system. 
 
Spermatogenesis 
The production of spermatozoa (spermatogenesis) takes place in the testes. By fibrous septa, 
the testes are divided into several lobules. These lobules contain the seminiferous tubules, 
which collect the spermatozoa once they are produced. The production occurs by a series of 
divisions and subsequent differentiation from sperm stem cells (spermatogonia) located in the 
epithelium of the seminiferous tubules. The epithelium also contains Sertoli cells, which 
support, protect and nourish the developing spermatogenic cells. Moreover, the Sertoli cells 
help in regulation of the differentiation of spermatogonia.   
 
In male dogs, FSH is the gonadotropic hormone that is responsible for stimulation of the Sertoli 
cells, which in turn affect spermatogenesis and promote the production of mature spermatozoa. 
FSH also stimulates the Sertoli cells’ own development and function (Feldman and Nelson, 
2004). 
 
Testosterone 
In the intertubular space, between the seminiferous tubules, clusters of Leydig cells are located. 
Leydig cells are steroid-producing cells, responsible for the formation of testosterone. The 
testosterone production is triggered by LH mediated stimulation of the Leydig cells (Feldman 
and Nelson, 2004).  
 
Testosterone is a cholesterol derived hormone, with a hydroxyl group connected to its steroid 
skeleton. In the blood, testosterone is transported bound to sex hormone binding globulin 
(SHBG) protein. In some tissues, testosterone is converted to dihydrotestosterone, which has 
approximately twice as much biological potency as testosterone (Feldman and Nelson, 2004). 
Testosterone can also be aromatized to oestrogen in many tissues, especially in adipose tissue. 
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Testosterone has several functions: 
 
 Together with FSH, it promotes spermatogenesis. 
 It maintains secretory and absorptive activities in the male sperm duct system. 
 It promotes growth and maintenance of the prostate gland. 
 During fetal development, testosterone is responsible for differentiating the external 
genitalia into the penis and the scrotum. Testosterone also converts the Wolffian duct 
(the precursor structure for the male internal genitalia) into the male reproductive duct. 
 It promotes development of primary sex characteristics, which is growth of the 
internal and external genitalia that distinguishes males from females.  
 It promotes development of secondary sexual characteristics (traits that distinguish 
males from females), such as increased muscle mass, increased hair growth, increased 
secretion of female attracting pheromones and stronger sex drive (libido).  
 
Plasma concentration of testosterone fluctuates during the day, because GnRH and 
subsequently both FSH and LH, is secreted in regular and brief pulses (Feldman and Nelson, 
2004). In male dogs, after a peak in GnRH, plasma concentration of LH and testosterone peak 
approximately 15 and 60 minutes later, respectively.  
 
Testicular testosterone concentrations are 50 to 100 times greater than concentrations in blood 
(Feldman and Nelson, 2004). Therefore, blood concentrations may not reflect alterations in 
testicular testosterone, nor be a useful diagnostic aid for evaluating spermatogenesis. However, 
measurement of blood testosterone provides information on the functional status of the 
hypothalamic-pituitary-gonadal axis.  
 
The relationship between testosterone and male fertility 
The definition of fertility is the ability to produce a viable offspring, while infertility is the lack 
of that ability (NE, 2015). Infertility in dogs can be either acquired or congenital, with normal 
or decreased libido.  
 
Infertility is associated with several abnormalities in spermatogenesis, e.g. azoospermia 
(complete absence of spermatozoa in the ejaculate), oligospermia (decrease in the total number 
of spermatozoa per ejaculate), teratozoospermia (increased numbers of abnormal spermatozoa 
per ejaculate) and asthenozoospermia (decreased motility of spermatozoa in an ejaculate) 
(Feldman and Nelson, 2004). 
 
Both libido and sperm production are dependent on an intact hypothalamic-pituitary-testicular 
axis, and testosterone promotes libido and spermatogenesis. Therefore, testosterone plays an 
important role in maintaining fertility. Decreased libido in an infertile dog may result from 
destruction of the Leydig cells, and decreased testosterone production within the testes 
(Feldman and Nelson, 2004). Lower blood testosterone concentrations can be expected in most 
dogs with decreased libido. Dogs with normal libido and the ability to mate rarely have plasma 
testosterone concentrations below 0.4 ng/ml, regardless of fertility.  
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Anti-Müllerian Hormone 
Anti-Müllerian Hormone (AMH) is a dimeric hormone of the TGF-β family, found only in 
gonadal somatic cells (Wilson et al., 1993). During testicular development, AMH is secreted 
from immature Sertoli cells. Together with testosterone secreted from the Leydig cells, AMH 
causes the fetus to develop as a male. During early development, AMH is responsible for the 
regression of the Müllerian ducts, the precursor structure for the female internal genitalia 
(Sjaastad et al., 2010). Since FSH is responsible for stimulation of Sertoli cells, FSH also 
regulates AMH secretion (Lukas-Croisier et al., 2003). 
 
Secretion of AMH in men is maintained high until puberty (Josso and di Clemente, 1999, 
Rajpert-De Meyts et al., 1999). After puberty, expression of AMH in human gonadal tissue 
decreases, which is believed to reflect terminal maturation of the Sertoli cells (Rajpert-De 
Meyts et al., 1999). The same relationship has been seen in dogs. In an immunohistochemical 
study by Banco et al., AMH expression was high in fetal and young puppies, but diminished in 
puppies from 45 days of age (Banco et al., 2012). In canine Sertoli cell tumours and testicle 
degeneration (a risk factor for tumour development), AMH is instead increased (Banco et al., 
2012, Giudice et al., 2014, Holst and Dreimanis, 2015). 
 
The relationship between AMH and male fertility 
Infertile adult men with dysfunctional hypothalamic-pituitary-gonadal axis, such as 
hypogonadotropic hypogonadism (impaired secretion of FSH, LH and testosterone) had higher 
AMH plasma concentrations than normal men (Young et al., 1999). The opposite results were 
shown in another study from 2005. When comparing AMH in fertile and infertile men, serum 
concentrations of AMH were significantly higher in fertile men (Al‐Qahtani et al., 2005).  
 
The association between obesity and reduced male fertility  
Obesity is associated with subfertility in men, by causing altered semen parameters (e.g. 
decreased sperm concentration, abnormal sperm morphology and abnormal sperm motility), 
altered profile of sex hormones, and physical disorders such as erectile dysfunction (Cabler et 
al., 2010).  
 
A large study conducted on 1558 Danish men, reported that high BMI was associated with 
alterations in semen parameters such as lower sperm concentration and total sperm count. Also, 
higher BMI was associated with lower percentage of normal spermatozoa (Jensen et al., 2004). 
Lower sperm concentration in obese men was also seen in a study by Hammoud et al., together 
with reduced progressively motile sperm count (Hammoud et al., 2008). On the other hand, a 
meta-analysis from 2010 on studies on humans could not demonstrate a relationship between 
semen parameters (sperm concentration, total sperm count, semen volume, motility and 
morphology) and BMI (MacDonald et al., 2010).  
 
 
 
Erectile dysfunction causes reproductive difficulties and has been reported in obese men in 
several studies. In a cross-sectional study of 149 obese men, decreased libido occurred in 22,5 
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% and erectile dysfunction in 31,7 % (Hofstra et al., 2008). Corona et al (2006) reported an 
even higher prevalence; out of 236 obese males diagnosed with metabolic syndrome, 96,5 % 
had erectile dysfunction (Corona et al., 2006). 
 
Sex hormones and fertility among obese men 
In the earlier mentioned meta-analysis by MacDonald et al. (2010), strong evidence of a 
negative correlation between BMI and testosterone, SHBG and free testosterone was shown 
(MacDonald et al., 2010). Hofstra et al. also reported that low testosterone serum 
concentrations, consistent with hypogonadotropic hypogonadism, was frequently occurring in 
male obesity (Hofstra et al., 2008). Low testosterone serum concentrations among obese men 
has also been reported in other studies, and serum concentrations have been shown to increase 
after weight loss (Kaukua et al., 2003, Fejes et al., 2006, Håkonsen et al., 2011, Pellitero et al., 
2012, Robeva et al., 2012). 
 
Several studies state that oestrogen is the cause of lowered testosterone concentrations in obese 
men, since they express a characteristic hormonal profile described as “hyperestrogenic 
hypogonadotropic hypogonadism”, i.e. low serum testosterone concentrations caused by 
increased conversion of testosterone to oestrogen in the increased mass of adipose tissue. The 
higher concentrations of oestrogen then exert a negative feedback on LH secretion, and 
testosterone production therefore also decreases (Hammoud et al., 2006, Hofstra et al., 2008). 
Two studies support this hypothesis; a positive correlation between oestrogen and BMI was 
seen in the study of Håkonsen et al. (2011), and weight loss in obese men caused a decrease in 
oestrogen levels (Pellitero et al., 2012). 
 
Regarding AMH, two studies in humans show that serum concentrations are lower in obese 
patients than in patients with normal body weight (Pietiläinen et al., 2011, Robeva et al., 2012). 
and one study shows that weight loss increases AMH serum concentrations (Håkonsen et al., 
2011).  
 
MATERIAL AND METHODS 
Study design 
The analyses in this study were conducted at the Swedish University of Agricultural Sciences 
(SLU), Uppsala, Sweden, in spring 2015. Testosterone and AMH was measured by enzyme-
linked immunosorbent assay (ELISA) analysis of already collected blood samples from male 
Labrador retrievers. The AMH ELISA had earlier been used for dogs (Holst and Dreimanis, 
2015) and a brief validation of the testosterone ELISA was performed in this current study. The 
blood samples were originally collected in 2012-2013 for an accepted, yet unpublished study 
(Söder et al., in press 2015). Some of them were also used in another study (Hillström et al., 
2015). The samples were divided into aliquots, stored in -80 °C. 
  
Animals and inclusion criteria 
The study population consisted of 28 intact male show-type Labrador retrievers. The dogs 
weighed 31,5-48 kg and were 1-9 years old.  
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To be included in the study, the dog had to be considered healthy by its owner, and pass the 
clinical health examination conducted at SLU. Furthermore, no history or presence of systemic 
or organ-related diseases was accepted, nor treatment with antibiotics, non-steroid anti-
inflammatory drugs, steroids, deworming drugs or proton pump inhibitors within three months 
of the examination day.  
 
Conduction of the study 
Before arriving to the clinic, all dogs had undergone fasting for 14-17 hours. On arrival, the 
clinical health examination was conducted by the same veterinarian for all dogs, and the dogs 
were weighed. To rule out any signs of systemic or organ-related disease, routine analyses of 
hematology, biochemistry and urine were performed. Subsequently, the fasting serum samples 
were taken.  
 
All dogs had been classified according to the 1-9 point scale BCS (Laflamme, 1997) by one 
single veterinarian. The dogs were grouped into lean (BCS 4-5) or overweight (BCS 6-8). 
 
Hormone analysis 
Testosterone and AMH were analysed by commercially available human ELISA assays (AMH 
Gen II ELISA, Beckman coulter, and testosterone ELISA, IBL International, GmBH).  
 
Statistical analysis  
The two-sample t-test was used for comparison of body weight and age between groups. The 
non-parametrical Mann-Whitney U-test was used for comparison of testosterone and AMH 
concentrations between the lean and overweight dogs, because of non-normal distribution of 
data. Significance level was set at P < 0.05.  
 
Testosterone ELISA validation 
A brief validation of the human testosterone ELISA, IBL International, GmBH, was performed 
for canine serum. The samples used in the validation were originally collected from intact male 
dogs for a previous study. A total of 27 samples were run on three ELISA-plates, in triplicate 
the first time and duplicate the last two times.   
 
Intra-assay coefficient of variability (CV) was obtained from analyses of results of five samples 
with concentrations between 5 and 10 nmol/L, and one sample with a concentration of 15 
nmol/L, analysed once in triplicate. Inter-assay CV was calculated after analyzing aliquots of 
three samples (3-7 nmol/L, 10-14 nmol/L and >17 nmol/L), analysed twice in duplicate. 
 
 
Linearity upon dilution was studied by diluting (9/10 to 1/10) two samples with dilution media. 
One of the samples had peaked above the highest calibrator (Dog A) and the other sample had 
a measured concentration of 8.92 nmol/L (Dog B). After dilution, observed results were plotted 
against the expected values and a regression fit was performed (Figures 2-5).  
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Validation results 
The intra-assay CV was <6 % for testosterone concentrations of 5-10 nmol/L and 4% for a 
concentration of 15 nmol/L. The inter-assay CV was 50 % for samples with concentrations of 
3-7 nmol/L, 37% for samples of 10-14 nmol/L and 5 % for samples >17nmol/L. After dilution 
of sample A and B and subsequent construction of simple linear regression models, linearity 
upon dilution was confirmed (R2 = 94.8% and 95.6%, respectively). Recovery upon dilution 
was 45-111% and 74-100%, respectively. In the serial dilution of the canine serum sample A, 
the ELISA was unable to measure the three highest values correctly (Figure 2-3), even though 
these values were expected to be below the highest calibrator (16 ng/mL, 55.5 nmol/L).  
 
 
 
 
Figure 2. Serial dilution of a canine serum sample A illustrating adequate linearity with 
regression fit of measured concentrations of testosterone. The three highest values were 
excluded in the graph since the ELISA was unable to measure them correctly.  
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Figure 4. Serial dilution of canine serum sample B illustrating adequate linearity with 
regression fit of measured concentrations of testosterone. 
 
 
 
Figure 5. Expected and observed values of testosterone in canine serum sample B.  
 
 
Figure 3. Expected and observed values of testosterone in canine serum sample A. The three 
highest values were not measured correctly, even though they were expected to be below the 
highest calibrator.  
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RESULTS 
Parts of the results were presented at the Animal Obesity Congress in Uppsala, Sweden, 14th-
16th of June 2015 (Andersson et al., 2015). Twelve dogs were classified as lean and 16 were 
classified as overweight (Table 2). Body weight differed significantly between groups (P = 
0.002). Age did not differ significantly between groups (P = 0.91).   
 
Table 2. Mean variables (age and weight) ± standard deviation (SD) of the 28 Labrador retrievers 
included in the study. 
  Lean 
BCS 4-5 
n=12 
Overweight 
BCS 6-8 
n=16 
Age (year)  5.3 ± 1.4 5.2 ± 1.6 
Body weight (kg) 
 
 34.8 ± 2.5 39.5 ± 4.7 
 
Testosterone results from three dogs from the overweight group were excluded due to technical 
problems. Median concentration and inter-quartile range was 9.6 ng/mL (7.4-14.1) for AMH 
and 9.7 nmol/L (6.3-15.4) for testosterone. The AMH concentrations in all dogs ranged between 
5.21 and 22 ng/mL (Figure 6). The testosterone concentrations in all dogs ranged between 1.58 
and 20.16 nmol/L (Figure 7). Serum concentrations of testosterone and AMH did not differ 
significantly between lean and overweight dogs (P = 0.11 and P = 0.63, respectively). 
 
 
 
Figure 6. Serum concentration of Anti-Müllerian hormone (AMH) in lean (BCS 4-5) and 
overweight (BCS 6-8) male Labrador retrievers.  
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Figure 7. Serum concentration of testosterone in lean (BCS 4-5) and overweight (BCS 6-8) male 
Labrador retrievers. Testosterone results from three dogs were excluded due to technical 
problems.  
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DISCUSSION 
In this study, serum concentrations of testosterone and AMH did not differ significantly 
between the lean and overweight group of dogs (i.e. BCS had no impact on serum concentration 
of testosterone or AMH in male dogs). It is possible that the lack of difference is true. The 
results could also be due to several other reasons. Firstly, the sample population might have 
been too small, only 28 dogs, and the power of the study thus limited. In contrast, the human 
studies referred to in this thesis include considerably larger study populations, with wider spans 
in BMI, which may reveal even small differences between obese and normal weight groups.  
 
Also, the BCS in the overweight dogs was rather low (only mild overweight). The choice of the 
Labrador retriever for the study was because it is the most common dog breed in Sweden (SKK 
Registreringsstatistik, 2014) and because it is a breed prone to obesity (Edney and Smith, 1986, 
Colliard et al., 2006, Lund et al., 2006, Corbee, 2013, Raffan et al., 2014). Using only one breed 
also makes the study population more homogenous. Even though body weight differed 
significantly between groups (P = 0.002), we did not manage to recruit really overweight, and 
at the same time healthy, dogs (only one dog had BCS 8) to the overweight group. The recruiting 
difficulties may be coupled to feelings of guilt among owners of obese dogs.  
 
In general, one difficulty when writing this thesis, was the lack of canine studies in this field of 
reproduction and obesity. Therefore, instead much focus has been on human studies for 
comparison. Our hypothesis was that overweight dogs have lower testosterone and AMH 
concentrations than lean dogs, because that is what has been proven in men.  
 
The cause of lowered AMH concentrations in obese men is unclear. Some studies found that 
testosterone has an inhibitory role on testicular AMH secretion in men (Rey et al., 1993, Young 
et al., 1999). If this is true, and if obese patients really express hyperestrogenic 
hypogonadotropic hypogonadism as earlier mentioned, high AMH concentrations is to be 
expected because of the lower testosterone concentrations. This is inconsistent with the more 
recent results showing that obese men have lowered AMH concentrations. The authors 
hypothesized that the low AMH concentrations depend on Sertoli cell impairment, caused by 
the anomalies associated with obesity, such as insulin resistance and higher concentrations of 
adipocytokines in the adipose tissue (Robeva et al., 2012). It is well known that, to a large 
extent, the adipocytokines expressed in both human and canine adipose tissue are 
proinflammatory, such as IL-6 and TNFα (Coppack, 2001, Ryan et al., 2010). Maybe the 
inflammatory state in obese individuals suppresses the Sertoli cells and hence AMH production. 
Against this background, we wanted to investigate what applies to male dogs regarding AMH 
and obesity. 
 
Even though AMH in our study did not differ significantly between the lean and overweight 
dogs, AMH concentrations were generally high compared to what has been shown in an earlier 
study on AMH in dogs (Holst and Dreimanis, 2015), using the same ELISA. In the study by 
Holst and Dreimanis, healthy dogs did not have higher AMH concentrations than 10 ng/mL, 
and dogs with Sertoli cell tumours (SCTs) had values > 22 ng/mL. Some dogs with non-
neoplastic testicular pathologies, or testicular tumours other than SCTs, had AMH values 
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between 10-22 ng/mL. These results are consistent with other studies that reported expression 
of AMH in canine SCTs (Banco et al., 2012), and increased expression of AMH in dogs with 
testicular atrophy (a risk factor for tumour development) (Giudice et al., 2014). As earlier 
mentioned, AMH is considered to be a useful marker of Sertoli cell maturation. It is likely that 
with testicular degeneration, the Sertoli cells may regress and become more immature, which 
in turn causes them to produce more AMH.   
 
In our study, three dogs had AMH concentrations higher than 22 ng/mL, and eleven dogs had 
AMH concentrations between 10 and 22 ng/mL. It seems unlikely that so many dogs in our 
study population would have testicular neoplastic changes or testicular degeneration, but 
unfortunately, in this study the dogs’ testicles were only evaluated by palpation, without finding 
any abnormalities. By palpation only, minor testicular lesions cannot be ruled out, which is a 
limitation in our study. It would have been better to combine testicular palpation with 
ultrasonography or histopathological examination, but due to financial and practical 
circumstances, this was not possible. It would also have been interesting to collect concurrent 
semen samples and information on libido from the participating dogs, to be able to study sperm 
morphology and hence further investigate the association between BCS and fertility. 
 
Regarding the testosterone in our study, results from three dogs were excluded due to technical 
problems; these three samples peaked above the highest calibrator. Unfortunately, we did not 
have the opportunity to run these samples again after dilution. On behalf of The Council of The 
Endocrine Society, Rosner et al. (2007) have reviewed the current utility and limitations in 
measuring testosterone in humans. They conclude that direct assays such as ELISA 
immunoassays are commonly used for measuring testosterone, but that they have several 
shortcomings, e.g. the risk of matrix effects, such as interfering proteins or cross-reacting 
steroids. Because of these problems, Rosner et al. (2007) recommends extraction of such 
interfering molecules and thereafter mass spectrometry as the gold standard for testosterone 
measurement in humans. With mass spectrometry, the chemical structure of the testosterone 
molecule is identified. Liquid chromatography mass spectrometry (LC-MS/MS) has recently 
been used in a pilot study on pregnant and nonpregnant bitches, where endogenous steroids 
were measured with promising results (Holst et al., 2015). Because of financial circumstances, 
the use of extraction and mass spectrometry was not possible in our current study. Holst et al. 
(2015) also states the LC-MS/MS method should be further validated before it can be used for 
routine diagnostics of canine samples. 
 
In general, other difficulties with measuring testosterone includes the diurnal secretion pattern 
of GnRH and therefore also testosterone. To minimize influence of this on our results, all 
samples were collected at the same time during the day, 08.00-10.00, when testosterone serum 
concentration peaks, as recommended by The Endocrine Society (Rosner et al., 2007, Bhasin 
et al., 2013). Also, at least in humans, testosterone concentration varies depending on age and 
gender. This potential error was minimized in our study since age did not differ significantly 
between groups and all were intact male dogs. Though, as far as the authors know, what applies 
to dogs according to time of peak concentration and age and gender fluctuations, has not been 
investigated.  
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Human error may also influence the test results in several steps in the analysis process, for 
example when pipetting the sample into the ELISA wells. Another crucial step is when rinsing 
the wells with wash buffer after incubation, to wash away samples and enzyme conjugate. To 
minimize these errors, good laboratory practice and analyse method instructions were followed 
carefully.  
 
The testosterone ELISA validation 
The testosterone molecule structure is well preserved among humans and dogs. Though, since 
there are a lot of challenges in the measurement of testosterone even in humans, and since 
matrix effects may vary between species, we decided to do a brief validation of the testosterone 
ELISA assay for canine serum in our current study. Because the AMH ELISA used in this study 
had earlier been used in dogs (Holst and Dreimanis, 2015), no validation was performed on 
AMH.  
 
As Rosner et al. (2007) reports, in humans most trouble lies in measuring testosterone with 
accuracy in the low ranges of concentration, which is clinically important for humans in 
diagnosis of e.g. hypogonadism and PCOS. In males, a total testosterone < 200 ng/dl (6.9 
nmol/L) is diagnostic of hypogonadism (Rosner et al., 2007). In the validation performed in 
this study, the ELISA measured these values in the low range of concentration without major 
problems. Also, most of the dogs had testosterone values above or around 6.9 nmol/L. However, 
in the serial dilution of samples from dog A the ELISA was unable to correctly measure the 
three highest values of testosterone, even though these values were expected to be below the 
highest calibrator (< 16 ng/ml, 55.5 nmol/L). The inter-assay CV for low and medium 
concentrations was high (37-50%), whereas the CV was 5% for the highest concentrations.  
 
In general, the values in the low range of concentration are not clinically as important in dogs 
as in humans. Blood testosterone concentrations may be helpful in differentiating intact versus 
castrated versus bilaterally cryptorchid dogs. The basal concentration of testosterone in normal 
dogs alters between 1 and 5 ng/ml (3.47 and 17.35 nmol/L), meanwhile in a cryptorchid dog 
between 0.1 and 2 ng/ml (0,35 and 6,94 nmol/L) (Feldman and Nelson, 2004). 
 
It is undesirable that the ELISA shows lack of accuracy in the high range of testosterone 
concentration. Because of this, if one is to use this IBL human testosterone ELISA for canine 
purposes, it can be recommended to dilute peaking samples to secure more correct measurement 
of the testosterone concentrations. This is preferably done by running duplicates of the samples, 
where each sample is run in 1:1 and also by dilution to 1:2. E.g., since the peaking values in 
this study were expected to be below the highest calibrator, a peaking sample should in reality 
not exceed 16 ng/ml (55.5 nmol/L). If this peaking sample is diluted to 1:2, it should be 8 ng/ml 
(27.8 nmol/L), and then be measured correctly since it then is well under the highest calibrator. 
 
In conclusion, the testosterone validation showed that the IBL human testosterone ELISA is 
acceptable, though not optimal, to use for canine study purposes. To optimize the validation 
procedure, we should have included more ELISA runs, and thereafter validated our ELISA 
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against the gold standard mass spectrometry analysis method. For financial and practical 
reasons, only a limited validation was performed in the present study. 
 
CONCLUSION 
In the present study, serum concentrations of testosterone and AMH did not differ significantly 
between lean and overweight dogs. This may be correct, but also limitations of the study and 
technical aspects could have influenced the results.  
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